Idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura)

  • 378 views
Uploaded on

H2 2012 Aarkstore.com | Idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura)

H2 2012 Aarkstore.com | Idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura)

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
378
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
8
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • www.aarkstore.in

Transcript

  • 1. You can also request for sample page of abovemention reports on sample@aarkstore.com
  • 2. Pages : 113PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $6000 |
  • 3. SummaryGlobal Markets Direct’s, Idiopathic Thrombocytopenic Purpura (ImmuneThrombocytopenic Purpura) - Pipeline Review, H2 2012, provides an overviewof the indication’s therapeutic pipeline. This report provides information on thetherapeutic development for Idiopathic Thrombocytopenic Purpura (ImmuneThrombocytopenic Purpura), complete with latest updates, and special featureson late-stage and discontinued projects. It also reviews key players involved inthe therapeutic development for Idiopathic Thrombocytopenic Purpura(Immune Thrombocytopenic Purpura). Idiopathic Thrombocytopenic Purpura(Immune Thrombocytopenic Purpura) - Pipeline Review, Half Year is built usingdata and information sourced from Global Markets Direct’s proprietarydatabases, Company/University websites, SEC filings, investor presentationsand featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.
  • 4. Scope- A snapshot of the global therapeutic scenario for Idiopathic ThrombocytopenicPurpura (Immune Thrombocytopenic Purpura).- A review of the Idiopathic Thrombocytopenic Purpura (Immune ThrombocytopenicPurpura) products under development by companies and universities/researchinstitutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Idiopathic Thrombocytopenic Purpura (Immune ThrombocytopenicPurpura).- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.
  • 5. Table of Contents :List of Tables 7List of Figures 8Introduction 9Global Markets Direct Report Coverage 9Idiopathic Thrombocytopenic Purpura (Immune ThrombocytopenicPurpura) Overview 10Therapeutics Development 11An Overview of Pipeline Products for Idiopathic Thrombocytopenic Purpura(Immune Thrombocytopenic Purpura) 11Idiopathic Thrombocytopenic Purpura (Immune ThrombocytopenicPurpura) Therapeutics under Development by Companies 13Idiopathic Thrombocytopenic Purpura (Immune ThrombocytopenicPurpura) Therapeutics under Investigation by Universities/Institutes 15Late Stage Products 17Comparative Analysis 17Mid Clinical Stage Products 18Comparative Analysis 18Early Clinical Stage Products 19Comparative Analysis 19Pre-Clinical Stage Products 20Comparative Analysis 20………………
  • 6. Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2 2012&PubId=&pagenum=1
  • 7. Related Reports:Uterine Cancer – Pipeline Review, H2 2012Depression – Pipeline Review, H2 2012Inflammatory Bowel Disease – Pipeline Review, H2 2012Squamous Cell Carcinoma – Pipeline Review, H2 2012Soft Tissue Sarcoma – Pipeline Review, H2 2012Age Related Macular Degeneration – Pipeline Review, H2 2012 MotorNeurone Diseases – Pipeline Review, H2 2012Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H2 2012T-Cell Lymphomas – Pipeline Review, H2 2012Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2012Throat Cancer – Pipeline Review, H2 2012Chronic Pain – Pipeline Review, H2 2012Germ Cell Tumors – Pipeline Review, H2 2012Alcohol Addiction – Pipeline Review, H2 2012Indolent Lymphoma – Pipeline Review, H2 2012Wounds – Pipeline Review, H2 2012
  • 8. For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: enquiry@aarkstore.com ,discount@aarkstore.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore